Form 4: Twist Bioscience CEO Emily Leproust Reports Stock Sale to Cover Tax Obligations
SEC Form 4
Emily Leproust, CEO of Twist Bioscience, sold 1,128 shares of common stock on March 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
Summary
- On March 20, 2024, Emily M. Leproust, CEO of Twist Bioscience, sold 1,128 shares of common stock at a price of $33.516 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
- Following the transaction, Leproust directly owns 515,281 shares of Twist Bioscience.
- Leproust also holds various employee stock options with different exercise prices and expiration dates.
- These options include 24,360 shares exercisable at $5.95, 150,879 shares at $8.82, 266,539 shares at $26.66, 131,290 shares at $23.33, and 64,950 shares at $67.85.
Sentiment
Score: 5
Explanation: This is a neutral event. The stock sale is related to tax obligations and doesn't necessarily indicate a change in the executive's confidence in the company.
Industry Context
This is a routine Form 4 filing related to insider stock transactions. It is common for executives to sell shares to cover tax obligations related to vesting equity awards.
Key Dates
| Date | Description |
|---|---|
| 12/19/2022 | Performance stock options vested and became exercisable. |
| 03/20/2024 | Emily Leproust sold 1,128 shares of Twist Bioscience common stock. |
| 03/22/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.